NEWTON, Mass.--(BUSINESS WIRE)--Please replace the release dated March 21, 2017, with the following corrected version due to multiple revisions.
The corrected release reads:
SIAMAB THERAPEUTICS TO PRESENT NEW PRECLINICAL DATA FOR ITS NOVEL ANTIBODIES AND ANTIBODY-DRUG CONJUGATES AT THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING 2017
Siamab Therapeutics, Inc., a biopharmaceutical company developing novel cancer immunotherapies, today announced it will present preclinical data for its novel anti-Sialyl-Tn (STn) and anti-CD3 bispecific antibodies and antibody-drug conjugates (ADCs) during two poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2017, being held April 1-5, 2017, at the Walter E. Washington Convention Center in Washington, D.C. Siamab will present data at this conference discussing the company’s success in targeting tumor-associated carbohydrate antigens (TACAs) and will show data demonstrating that myeloid derived suppressor cells (MDSCs) express TACA antigens and therefore have the potential to be targeted with Siamab’s antibody-based therapies.
Siamab is leveraging its proprietary technology platform to discover and develop monoclonal antibody (mAb) therapeutics that bind to TACAs, a novel class of cancer-specific targets. ST1, the company’s lead program, is in late stage preclinical development and is expected to enter human clinical trials in 2018.
Abstract Title and Number: Novel
anti-Sialyl-Tn monoclonal antibodies and antibody-drug conjugates (ADCs)
demonstrate tumor specificity in vitro and in vivo
antitumor efficacy (#36)
Date and Time: Sunday, April 2, 2017, 1:00-5:00 p.m. ET
Session: PO.ET07.01 - Antibodies, Bispecifics, and Antibody-Drug Conjugates
Location: Convention Center, Exhibit Halls A-C, Lower Level, Poster Section 2
Poster Number: 17
Abstract Title and Number: Novel
humanized anti-Sialyl-Tn, anti-CD3 bispecific antibodies demonstrate
tumor and T-cell specificity for immune activation at the tumor site
Date and Time: Tuesday, April 4, 2017, 8:00 a.m.-12:00 p.m. ET
Session: PO.IM02.05 - BITES Bispecifics and Checkpoints
Location: Convention Center, Exhibit Halls A-C, Lower Level, Poster Section 26
Poster Number: 13
The accepted abstracts are now available online on the AACR conference website at www.aacr.org.
About Siamab Therapeutics, Inc.
Siamab Therapeutics, Inc. is a biopharmaceutical company developing novel cancer immunotherapies targeting cancer-specific carbohydrate antigens seen in multiple solid tumors. Siamab has developed a platform that enables the rapid discovery and development of therapeutic antibodies that bind with unprecedented specificity and affinity to this novel class of carbohydrate antigens present on cancer cells called tumor associated carbohydrate antigens (TACAs). TACAs are an exciting cancer target class due to their cancer specificity, association with a chemoresistant phenotype, and ability to suppress immune function in the region of solid tumors. The company’s lead program, ST1, targets Sialyl-Tn (STn), a tumor specific antigen seen in multiple solid tumors including ovarian, pancreatic, prostate and colon cancers. ST1 is in preclinical studies for the treatment of solid tumors. Visit www.siamab.com to learn more about the company.